First, medications used by those with diabetes, such as metformin, glucagon-like peptide-1 (GLP-1) receptor agonists and sodium–glucose cotransporter 2 (SGLT2) inhibitors, all have strong cardioprotective qualities [39–41], although the MINAP registry does not yet collect data on these medications. Here, GLP1R is linked to diabetes mellitus.